Acadia Pharmaceuticals Inc. — Form 8-K Summary
Business context and reporting period
Acadia Pharmaceuticals filed a Form 8-K dated September 24, 2026, under Items 7.01 and 8.01 to disclose topline Phase 2 results from the ongoing RADIANT program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
Clinical results and other key metrics
- Primary endpoint: At the 60 mg once-daily dose, SAPS-H+D changed by -12.6 from baseline versus -10.4 for placebo at week 6; standardized effect size was 0.26, with p=0.0603.
- Key secondary endpoint: CGI-S-ADP changed by -1.3 for 60 mg versus -0.9 for placebo; standardized effect size was 0.37, with nominal p=0.0077.
- The treatment-placebo difference increased through the six-week treatment period on both efficacy measures.
- The 30 mg dose showed minimal improvement relative to placebo.
- Analyses used the prespecified modified full analysis set population.
- Across both doses, adverse-event rates, serious-adverse-event rates, and discontinuations due to adverse events were similar to placebo.
- The company reported no QT-prolongation signal, no apparent negative impact on motor symptoms or cognition, and no deaths in the remlifanserin treatment arms.
The filing provides no new revenue, profit, cash-flow, margin, debt, liquidity, or other corporate financial metrics.
Material changes, outlook, and risks
- Acadia plans to continue enrolling two ongoing Phase 3 ADP studies while amending the program to remove the 30 mg dose arm.
- Detailed RADIANT Phase 2 safety and efficacy results are expected to be presented at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 16–19, 2026.
- Remlifanserin is also being evaluated in a Phase 2 study for psychosis associated with Lewy body dementia.
- The company cautioned that topline and preliminary clinical results may not predict future trial outcomes or support regulatory approval.
- Other identified risks include pharmaceutical development and regulatory risks, trial timing and results, the need for capital to fund development, intellectual-property protection, regulatory compliance, and dependence on the continued commercialization of Nuplazid and Daybue.
Important facts for investors to verify
- Confirm the full Phase 2 dataset, including detailed safety, subgroup, and statistical analyses, when presented at CTAD.
- Monitor whether the Phase 3 protocol amendments and removal of the 30 mg arm affect enrollment, trial design, timing, or statistical power.
- Verify whether future Phase 3 results replicate the reported 60 mg efficacy and safety findings.
- Review Acadia’s Form 10-Q for the period ended June 30, 2026, and subsequent filings for cash resources, funding requirements, and commercialization performance.